Vericel Corporation filings document regulatory disclosures for a commercial-stage biopharmaceutical company focused on cell therapies and specialty biologics for sports medicine and severe burn care. Recent Form 8-K reports furnish operating and financial results, preliminary estimates, guidance updates and business highlights tied to MACI, Epicel and NexoBrid.
Proxy and annual meeting filings describe board elections, advisory votes on executive compensation, auditor ratification and other shareholder voting matters. The filing record also identifies Vericel as a Michigan corporation and provides formal disclosure around governance, financial reporting events and product-related commercial performance.
Vericel Corporation reported strong growth for the first quarter of 2026, with total revenue up 30% to $68.4 million compared to $52.6 million a year earlier. MACI net revenue rose 22% to $56.4 million and Burn Care revenue grew 91% to $12.0 million, including Epicel revenue growth of 119%.
Gross margin improved to 72%, helping narrow the net loss to $6.3 million, or $0.12 per diluted share, from $11.2 million, or $0.23 per share. Non-GAAP adjusted EBITDA increased 195% to $9.6 million, and free cash flow reached $15.1 million.
The company ended the quarter with approximately $211 million in cash and investments and no debt. Vericel raised its full-year 2026 revenue guidance by $10 million to a range of $326 to $336 million, with higher targets for both MACI and Burn Care.
VCEL filed a Form 144 notice reporting proposed sale activity for Common shares tied to Fidelity Brokerage Services LLC. The filing shows 3,433 shares with an attributable value of $130,454.00 and identifier 50763319 dated 05/06/2026. The excerpt also lists restricted stock vesting events: 1,383 shares on 02/17/2026, 913 shares on 02/20/2026, and 1,137 shares on 02/22/2026.
Vericel Corp director Kevin F. McLaughlin reported compensation-related equity activity. He exercised 3,200 previously granted Restricted Stock Units (RSUs) into 3,200 shares of common stock, bringing his direct common stock holdings to 18,300 shares after the transactions.
On the same date, he received new awards of 3,200 RSUs and stock options for 8,000 shares of common stock at an exercise price of $33.43 per share. The new RSUs vest 100% on the earlier of April 29, 2027, or the first Annual Meeting of Stockholders following April 29, 2026, while the options vest over one year in equal monthly increments, contingent on continued service.
Vericel Corp director Alan L. Rubino increased his equity-based holdings through routine compensation awards and vesting. He acquired 3,200 shares of common stock via the vesting and conversion of previously granted Restricted Stock Units (RSUs), bringing his direct common stock holdings to 64,194 shares.
He also received a new grant of 3,200 RSUs, each representing a contingent right to one Vericel common share, which vest 100% on the earlier of April 29, 2027, or the first Annual Meeting of Stockholders following April 29, 2026. In addition, he was granted stock options for 8,000 shares at an exercise price of $33.43 per share, vesting in equal monthly increments over one year and expiring on April 29, 2036. These transactions reflect equity compensation and do not include any open-market purchases or sales.
Vericel Corp director Heidi Hagen reported routine equity compensation activity. She exercised 3,200 Restricted Stock Units into 3,200 shares of common stock, bringing her direct common stock holdings to 35,050 shares. She also received a new grant of 3,200 RSUs that vest 100% on the earlier of April 29, 2027 or the first Annual Meeting of Stockholders following April 29, 2026. In addition, she was granted stock options for 8,000 shares at an exercise price of $33.43 per share, vesting in equal monthly increments over one year and expiring on April 29, 2036. All transactions reflect awards and exercises rather than open‑market buying or selling.
Vericel Corp director Paul K. Wotton reported equity compensation activity rather than open-market trading. He exercised or converted 3,200 shares of Common Stock, bringing his direct holdings to 28,802 shares. The filing shows net share acquisitions only, with no reported sales.
Wotton also received new awards: 3,200 Restricted Stock Units and 8,000 stock options with a conversion or exercise price of $33.43 per share, expiring on April 29, 2036. The options vest over one year in equal monthly increments, while the RSUs vest 100% on the earlier of April 29, 2027 or the first annual stockholders meeting after April 29, 2026. Certain RSUs were deferred into Phantom Stock units under Vericel’s Deferred Compensation Plan and will be settled in shares of Common Stock at Wotton’s elected distribution date.
Vericel Corp director Lisa Wright reported equity compensation and a deferral election, with no open-market buying or selling. She exercised 3,200 Restricted Stock Units (RSUs) into an equal number of Phantom Stock units under Vericel’s Deferred Compensation Plan, and holds 15,851 shares of common stock afterward.
Wright also received a new grant of 3,200 RSUs, each representing one share of common stock, which vest 100% on the earlier of April 30, 2026, or the first Annual Meeting of Stockholders after April 30, 2025. In addition, she was granted stock options for 8,000 shares at an exercise price of $33.43, vesting in equal monthly increments over one year and expiring on April 29, 2036.
Vericel Corp director Robert L. Zerbe, M.D. reported equity compensation activity with no open-market buying or selling. On April 29, 2026, 3,200 Restricted Stock Units (RSUs) vested and were exercised into 3,200 shares of Vericel common stock, bringing his direct common stock holdings to 32,995 shares.
On the same date, he received new equity awards: a grant of 3,200 RSUs, each representing a contingent right to one share of common stock, that vest 100% on the earlier of April 29, 2027 or the first Annual Meeting of Stockholders following April 29, 2026, and a grant of stock options for 8,000 shares of common stock at an exercise price of $33.43 per share, vesting monthly over one year and expiring on April 29, 2036.
Vericel Corporation reported the results of its annual shareholder meeting held on April 29, 2026. Shareholders elected seven directors — Robert Zerbe, Alan Rubino, Heidi Hagen, Kevin McLaughlin, Paul Wotton, Lisa Wright and Dominick Colangelo — each to one-year terms. Votes "for" each director ranged from 38,296,679 to 45,198,344, with broker non-votes of 2,162,887 on each nominee. Shareholders also approved, on a non-binding advisory basis, the compensation of Vericel's named executive officers, with 36,350,150 votes for, 9,725,057 against and 30,539 abstentions, plus 2,162,887 broker non-votes. In addition, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, by 44,971,340 votes for, 3,275,442 against and 21,851 abstentions.
Vericel Corp reports institutional ownership disclosure by Vanguard Capital Management. Vanguard Capital Management states it beneficially owns 2,603,128 shares of Common Stock, representing 5.11% of the class. The filing shows sole voting power for 372,372 shares and sole dispositive power for 2,603,128 shares, with holdings held on behalf of various Vanguard affiliates and client accounts.